These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7067469)

  • 21. Investigating maximum power losses in survival studies with nonstratified randomization.
    Palta M
    Biometrics; 1985 Jun; 41(2):497-504. PubMed ID: 4027324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rank-Minimization for balanced assignment of subjects in clinical trials.
    Stigsby B; Taves DR
    Contemp Clin Trials; 2010 Mar; 31(2):147-50. PubMed ID: 20004741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical inference and the design of clinical trials.
    Berry DA
    Biomedicine; 1980 Feb; 32(1):4-7. PubMed ID: 7370380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A design for phase II testing of anticancer agents within a phase III clinical trial.
    Schaid DJ; Ingle JN; Wieand S; Ahmann DL
    Control Clin Trials; 1988 Jun; 9(2):107-18. PubMed ID: 3396362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential treatment allocation procedures in clinical trials--with particular attention to the analysis of results for the biased coin design.
    Halpern J; Brown BW
    Stat Med; 1986; 5(3):211-29. PubMed ID: 3738289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consultants' forum: should post hoc sample size calculations be done?
    Walters SJ
    Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A SAS macro for sample size adjustment and randomization test for internal pilot study.
    Wang S; Xia J; Yu L; Li C; Xu L
    Comput Methods Programs Biomed; 2008 Apr; 90(1):66-88. PubMed ID: 18192069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. To define sufficient subjects.
    Nairn RG; Morris T
    Aust N Z J Surg; 1980 Feb; 50(1):64-7. PubMed ID: 6928764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stopping rules and estimation problems in clinical trials.
    Hughes MD; Pocock SJ
    Stat Med; 1988 Dec; 7(12):1231-42. PubMed ID: 3231947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient heterogeneity in clinical trials.
    Simon R
    Cancer Treat Rep; 1980; 64(2-3):405-10. PubMed ID: 7407777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation of research data: hypothesis testing.
    Stolar MH
    Am J Hosp Pharm; 1980 Nov; 37(11):1539-45. PubMed ID: 7211860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Issues in designing sequential stopping rules for monitoring side effects in clinical trials.
    Goldman AI
    Control Clin Trials; 1987 Dec; 8(4):327-37. PubMed ID: 3327653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of screening and eliminating preexisting cases on sample size requirements for cancer prevention trials.
    Patterson BH
    Control Clin Trials; 1987 Jun; 8(2):87-95. PubMed ID: 3608509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maximum information designs.
    Lachin JM
    Clin Trials; 2005; 2(5):453-64. PubMed ID: 16315649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimize the use of minimization with unequal allocation.
    Proschan M; Brittain E; Kammerman L
    Biometrics; 2011 Sep; 67(3):1135-41. PubMed ID: 21281276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.
    Detsky AS; Sackett DL
    Arch Intern Med; 1985 Apr; 145(4):709-12. PubMed ID: 3985731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation.
    Stallard N; Rosenberger WF
    Stat Med; 2002 Feb; 21(4):467-80. PubMed ID: 11836730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.